Could a common supplement calm Kids' mood swings? new trial investigates

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Emotional Dysregulation Group 1. Male or female subjects, 6-12 years of age. 2. Current symptoms of emotional dysregulation as indicated by combined T-scores on the Child Behavior Checklist \> 180 on the Anxiety/Depression + Aggression + Attention subscales. 3. Score 15 or above on the clinician YMRS 4. Subjects and their legal representative must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol. 5. Subjects and their legal representative must be considered reliable. 6. Each subject and his/her authorized legal representative must understand the nature of the study. The subject's authorized legal representative must provide written consent and the subject must provide written assent. 7. Subject must have access to a computer with a camera, speaker, microphone, and internet connection. 8. Subject must be willing to refrain from treatment changes during the study protocol. Typically Developing Control Group 1. Age-, sex-matched with ED participants. 2. No significant traits of ED as screened by parent and clinician YMRS both under scores of 6 3. No previous psychiatric history as confirmed by clinician interview 4. No significant psychopathology as screened on the CBCL (Subdomain T-scores \<60). 5. Participant weight is above the 5th percentile and below the 95th percentile, per CDC child BMI categories (https://www.cdc.gov/obesity/basics/childhood-defining.html) Exclusion Criteria: 1. Investigator and his/her immediate family (defined as the investigator's spouse, parent, child, grandparent, or grandchild). 2. Serious or unstable illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease. 3. History of bleeding diathesis, including those with von Willebrand disease. 4. Uncorrected hypothyroidism or hyperthyroidism. 5. History of sensitivity to N-acetylcysteine, a history of intolerance to N-acetylcysteine or a non-responder after 2 months of treatment at adequate doses as determined by the clinician. 6. Severe allergies or multiple adverse drug reactions. 7. Current or past history of seizures. 8. DSM-IV substance use, abuse, or dependence 9. Any concomitant medication with primary central nervous system activity other than specified in the Concomitant Medication portion of the protocol. 10. Current diagnosis of schizophrenia or psychosis. 11. Females who have started menstruating. 12. Pregnant or nursing. 13. Judged to clinically be at serious suicidal risk or C-SSRS score ≥ 4. 14. History of intellectual disability as reported by parent